News

Top Affordable Healthcare Stocks: AbbVie and Pfizer Insight

Top Affordable Healthcare Stocks: AbbVie and Pfizer Insight

Resilience in the Healthcare Sector

The healthcare sector has long been recognized as a resilient domain for investors. Companies in this field provide essential life-saving medicines, devices, and solutions that consumers rely on, regardless of economic conditions. The steady demand for healthcare products and services makes these businesses a valuable addition to a diversified investment portfolio, suitable for various market scenarios.

Promising Healthcare Stocks

If you're searching for healthcare stocks with appealing valuations, consider two noteworthy options: AbbVie and Pfizer.

1. AbbVie

AbbVie (NYSE: ABBV) has faced a slowdown in growth due to the loss of patent exclusivity for its leading drug, Humira. However, the company has strategically adapted to lessen the financial impact of this change. While AbbVie is expected to enter a transition phase in the coming quarters as Humira sales decline, it boasts a portfolio of several blockbuster drugs and a promising pipeline that long-term investors should carefully evaluate before making decisions.

AbbVie's lineup includes several high-performing medications, such as Venclexta, a crucial treatment for blood cancer, and immunology drugs like Skyrizi, which treats plaque psoriasis, psoriatic arthritis, and Crohn's disease, as well as Rinvoq, used for conditions like eczema and rheumatoid arthritis. In the last quarter alone, these three drugs achieved impressive year-over-year revenue growths of 11.5%, 44.8%, and 55.8%, respectively.

The company has also launched newer drugs, including Vraylar for schizophrenia and bipolar disorder, along with migraine treatments Ubrelvy and Qulipta, all of which have seen significant revenue increases. In the most recent quarter, AbbVie's total revenue rose over 4% year-over-year to $14.5 billion, with net earnings reaching $1.4 billion.

In addition to advancing its drug development efforts, AbbVie has made significant acquisitions, such as Celsius Therapeutics and Cerevel Therapeutics. The acquisition of Celsius has added multiple new candidates to its pipeline, potentially leading to a first-in-class investigational drug for inflammatory bowel disease. Meanwhile, acquiring Cerevel has strengthened AbbVie's neuroscience portfolio with Emraclidine, a promising next-generation antipsychotic currently undergoing clinical trials.

Another attractive aspect for investors considering AbbVie is its dividend, which has consistently increased over time. Over the past five years, AbbVie’s dividend has risen by 45%. The current yield is approximately 3%, about double the average yield of S&P 500 stocks. This strong history of dividend growth, combined with a stable business outlook, makes AbbVie a stock worthy of further consideration.

2. Pfizer

Pfizer (NYSE: PFE) offers another appealing investment opportunity, currently trading at a price-to-sales (P/S) ratio of 3. Following a remarkable surge during the pandemic, fueled by unprecedented sales of its COVID-19 vaccine and antiviral treatment, Pfizer's growth metrics are starting to stabilize.

This stabilization does not indicate stagnation for Pfizer. The company has effectively reinvested profits from its COVID-19-related sales into internal development projects and strategic acquisitions. Recently, Pfizer has completed several acquisitions, including Biohaven Pharmaceuticals, known for its migraine medication Nurtec, and Arena Pharmaceuticals, which specializes in immuno-inflammatory drugs, as well as oncology leader Seagen.

Among these acquisitions, the Seagen deal is projected to contribute around $10 billion in annual revenue by 2030, while also introducing a suite of blockbuster oncology drugs to Pfizer’s already extensive portfolio. This acquisition not only enhances Pfizer's pipeline but also adds already approved oncology treatments, bolstering its market presence in cancer care.

Despite a decline in COVID-19-related sales, Pfizer generated over $55 billion in revenue over the past year, supported by an operating cash flow of about $8 billion. Although the stock has experienced some recent declines, Pfizer remains committed to maintaining its dividend, which has soared to nearly a 6% yield, significantly higher than the S&P 500's average of 1.5%. Notably, Pfizer’s dividend payout has increased by approximately 17% over the last five years.

With a robust 175-year history, Pfizer has successfully navigated various business cycles. There’s little reason to believe that this transitional period, following its pandemic highs, will deviate from that historical trend. Investors may find it advantageous to consider investing while the stock is priced below traditional valuations.

Investment Considerations

Before investing in AbbVie or Pfizer, it's crucial to assess your financial goals, risk tolerance, and how these stocks might fit into your overall investment strategy. Both companies offer unique strengths and potential growth paths that could align well with an investor’s long-term objectives.

Frequently Asked Questions

What makes AbbVie a good investment opportunity?

AbbVie has a diverse portfolio of blockbuster drugs, a strong history of dividend growth, and promising future potential due to ongoing product developments and acquisitions.

How has Pfizer adjusted post-pandemic?

Pfizer has refocused on internal development and strategic acquisitions as revenue normalizes after the pandemic, aiming to sustain its growth momentum.

What is the current dividend yield for AbbVie?

AbbVie currently offers a dividend yield of about 3%, which is quite attractive compared to the average yields of stocks in the market.

Why is the healthcare sector considered resilient for investments?

The healthcare sector typically shows strong demand even during economic downturns, making it a safer investment option for many investors.

What should investors consider before investing in these stocks?

Investors should evaluate their financial goals, risk appetite, and how either company fits within their overall investment strategies before making any purchases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 168

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 99

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 183

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 149

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 150

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 46

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading

Top 5 Most Recently Viewed Articles

Chuyuan Group's Transformative Journey Towards Sustainable Success

Updated Category News Views 226

Chuyuan Group's Path to Sustainability and Growth In recent years, Chuyuan Group has significantly transformed its operations, embracing high-quality development in response to the evolving regulatory landscape. As the industry landscape changes, companies like Chuyuan must adapt to remain competitive and environmentally responsible. Understanding the Shift: Old Yang and...

Continue Reading
Adani Bonds Face Downgrade Risk Amid U.S. Bribery Scandal

Updated Category News Views 355

Fitch Ratings Puts Adani Group Bonds on Negative Watch In a significant move, Fitch Ratings has placed bonds from various units of the Adani Group on a watchlist for potential downgrades. This action follows serious allegations against the conglomerate's top executives, who are facing U.S. charges related to bribery and fraud. Implications of the Watch Status Fitch's...

Continue Reading
Investigation of Arbor Realty Trust: What Investors Should Know

Updated Category News Views 81

Understanding the Investigation of Arbor Realty Trust Faruqi & Faruqi, LLP, a well-known national securities law firm, is currently looking into claims related to Arbor Realty Trust, Inc. (NYSE: ABR). Investors who have suffered losses exceeding $100,000 while investing in Arbor are encouraged to get in touch for more information and support. Who Should Reach Out to...

Continue Reading
Qualcomm's Strategic Move: Potential Intel Acquisition Talks

Updated Category News Views 185

Qualcomm's Interest in Intel's Assets Recently, Qualcomm has made headlines by showing interest in buying parts of Intel. This move seems to be a strategic effort by Qualcomm to strengthen its presence in the competitive technology market, especially within the chip manufacturing sector. Shifting Market Dynamics Intel, a leader in chip production, is currently facing...

Continue Reading
Refined Energy Corp Expands Partnership with Eagle Plains Resources

Updated Category News Views 113

Refined Energy Corp Strengthens Its Partnership Refined Energy Corp announces an important amendment to its agreement with Eagle Plains Resources Ltd. The key focus of this amendment is to enhance their collaboration on the Dufferin Project, a project located in Canada's Athabasca Basin, known for its rich mineral deposits. Details of the Amended Agreement In a recent...

Continue Reading